Association between Serotonin-Related Polymorphisms in 5HT2A, TPH1, TPH2 Genes and Bipolar Disorder in Korean Population.
OBJECTIVE
The aim of the present study was to examine the association between serotonin-related gene polymorphisms and bipolar disorder in the Korean population. In addition, we sought to explore the relationship between the clinical characteristics of bipolar patients and serotonin-related gene polymorphisms.


METHODS
Inpatients with bipolar disorder (n=103) and control subjects (n=86) were genotyped for 5HT2A 1438A/G, tryptophan hydroxylase 1 (TPH1) 218 A/C, and TPH2 703G/T. We divided patients with bipolar disorder into two groups according to the presence of psychotic symptoms. The severity of their symptoms was measured using the Young Mania Rating Scale (YMRS) and the Brief Psychiatric Rating Scale (BPRS).


RESULTS
There were no significant differences in the genotype distributions or allelic frequencies in the three serotonergic polymorphisms between patients with bipolar disorder and normal controls. There were significant differences in genotype distributions and allele frequencies of the 5-HT2A -1438A/G polymorphism between the psychotic mania group and the non-psychotic mania group (genotype: chi(2)=7.50, p=0.024; allele: chi(2)=5.92, p=0.015). However, after Bonferroni correction this signifact difference disappeared. We did not find significant differences in the genotype distributions or allelic frequencies in the TPH1 218 A/C and TPH2 703G/T polymorphisms between the psychotic mania group and non-psychotic mania group.


CONCLUSIONS
We failed to found the statistically significant association between three polymorphisms and bipolar disorder. However, there was a trend towards association between 5-HT2A -1438A/G polymorphism and psychotic symptom in bipolar disorder. Future research should seek to clarify this association.
Choi
Kwang-Yeon
KY
Department of Psychiatry, College of Medicine, Korea University, Ansan Hospital, Ansan, Korea.
Yoon
Ho-Kyoung
HK
Kim
Yong-Ku
YK
Bipolar Disord. 2008 Nov;10(7):816-21
19032713
Biochem Pharmacol. 2003 Nov 1;66(9):1673-80
14563478
Biol Psychiatry. 2006 Sep 15;60(6):621-9
16580642
Psychiatr Genet. 2001 Sep;11(3):111-4
11702051
Am J Med Genet. 2002 Jul 8;114(5):533-40
12116191
Psychiatr Genet. 2008 Oct;18(5):240-7
18797398
Science. 2003 Jan 3;299(5603):76
12511643
Arch Gen Psychiatry. 1998 Jul;55(7):593-602
9672049
Biol Psychiatry. 2007 Jan 15;61(2):181-6
16806105
Biol Psychiatry. 2007 Jan 15;61(2):167-73
16697352
Psychopharmacol Bull. 1988;24(1):118-21
3387515
BMC Med Genet. 2005 Mar 31;6:14
15799788
Arch Gen Psychiatry. 2007 May;64(5):543-52
17485606
Biol Psychiatry. 1997 Apr 1;41(7):768-73
9084895
Arch Gen Psychiatry. 2003 May;60(5):497-502
12742871
Psychopharmacology (Berl). 2005 Dec;183(3):378-82
16240163
Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):403-9
19162119
Biol Psychiatry. 2004 Sep 15;56(6):406-10
15364038
Neuropsychopharmacology. 2006 Feb;31(2):431-41
16123739
Br J Psychiatry. 1978 Nov;133:429-35
728692
Biol Psychiatry. 1999 Mar 1;45(5):603-14
10088047
Biol Psychiatry. 2004 Feb 15;55(4):428-33
14960297
Biochem Pharmacol. 1969 May;18(5):1071-81
5789774
Am J Med Genet B Neuropsychiatr Genet. 2004 Aug 15;129B(1):29-33
15274035
Neuroreport. 1998 Apr 20;9(6):1139-41
9601682
Mol Psychiatry. 1998 Jan;3(1):42-9
9491812
Arch Gen Psychiatry. 2007 Sep;64(9):1015-24
17768266
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jul 1;32(5):1293-7
18502553
Arch Gen Psychiatry. 1998 Jan;55(1):33-7
9435758
Mol Psychiatry. 1998 Jan;3(1):61-6
9491814